FGIN-1-27 - CAS 142720-24-9
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C28H37FN2O
Molecular Weight:
436.61
COA:
Inquire
Targets:
GABA Receptor
Description:
FGIN-1-27 is a high affinity agonist of mitochondrial benzodiazepine receptors (PBR) binding to benzodiazepine receptors on mitochondrial membranes. FGIN-1-27 indirectly potentiates GABAA receptor signaling to exhibit anticonvulsant, anxiolytic, and sedative activity in both animal and clinical models.
Brife Description:
PBR agonist
Purity:
≥98% by HPLC
Synonyms:
FGIN-1-27; FGIN 1 27; FGIN-1 27; FGIN 1-27; FGIN127; N,N-Dihexyl-2-(4-fluorophenyl)indole-3-acetamide; 2-[2-(4-fluorophenyl)-1H-indol-3-yl]-N,N-dihexylacetamide
MSDS:
Inquire
InChIKey:
VUWXAQFLTSBUDB-UHFFFAOYSA-N
InChI:
InChI=1S/C28H37FN2O/c1-3-5-7-11-19-31(20-12-8-6-4-2)27(32)21-25-24-13-9-10-14-26(24)30-28(25)22-15-17-23(29)18-16-22/h9-10,13-18,30H,3-8,11-12,19-21H2,1-2H3
Canonical SMILES:
CCCCCCN(CCCCCC)C(=O)CC1=C(NC2=CC=CC=C21)C3=CC=C(C=C3)F
1.Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents.
Ugale RR;Hirani K;Morelli M;Chopde CT Neuropsychopharmacology. 2004 Sep;29(9):1597-609.
Olanzapine increases brain allopregnanolone (ALLO) levels sufficiently to modulate neuronal activity by allosterically regulating GABAA receptors. Recently, we reported the antipsychotic-like profile of ALLO in rodents. The present study examined the hypothesis that olanzapine-induced elevation of endogenous neurosteroid ALLO is vital for its neuroleptic-like action. The conditioned avoidance response (CAR) and apomorphine-induced climbing behavioral paradigms were used in rodents. Administration of ALLO (1 microg, intracerebroventricular (i.c.v.)) or neurosteroidogenic agents such as the mitochondrial diazepam binding inhibitor receptor agonist, FGIN 1-27 (0.5 microg, i.c.v.) or the ALLO precursor, progesterone (10 mg/kg, i.p.) significantly potentiated olanzapine-induced blockade of CAR and apomorphine-induced climbing. In contrast, these agents failed to alter the antipsychotic-like effect of risperidone and haloperidol. On the other hand, inhibition of the endogenous biosynthesis of neurosteroids by the 3beta-hydroxysteroid dehydrogenase inhibitor, trilostane (30 mg/kg, i.p.), the 3alpha-hydroxysteroid oxidoreductase inhibitor, indomethacin (5 mg/kg, i.p.), or the GABAA receptor antagonist bicuculline (1 mg/kg, i.
2.Midazolam inhibits hippocampal long-term potentiation and learning through dual central and peripheral benzodiazepine receptor activation and neurosteroidogenesis.
Tokuda K;O'Dell KA;Izumi Y;Zorumski CF J Neurosci. 2010 Dec 15;30(50):16788-95. doi: 10.1523/JNEUROSCI.4101-10.2010.
Benzodiazepines (BDZs) enhance GABA(A) receptor inhibition by direct actions on central BDZ receptors (CBRs). Although some BDZs also bind mitochondrial receptors [translocator protein (18 kDa) (TSPO)] and promote the synthesis of GABA-enhancing neurosteroids, the role of neurosteroids in the clinical effects of BDZs is unknown. In rat hippocampal slices, we compared midazolam, an anesthetic BDZ, with clonazepam, an anticonvulsant/anxiolytic BDZ that activates CBRs selectively. Midazolam, but not clonazepam, increased neurosteroid levels in CA1 pyramidal neurons without changing TSPO immunostaining. Midazolam, but not clonazepam, also augmented a form of spike inhibition after stimulation adjacent to the pyramidal cell layer and inhibited induction of long-term potentiation. These effects were prevented by finasteride, an inhibitor of neurosteroid synthesis, or 17PA [17-phenyl-(3α,5α)-androst-16-en-3-ol], a blocker of neurosteroid effects on GABA(A) receptors. Moreover, the synaptic effects were mimicked by a combination of clonazepam with FGIN (2-[2-(4-fluorophenyl)-1H-indol-3-yl]-N,N-dihexylacetamide), a selective TSPO agonist, or a combination of clonazepam with exogenous allopregnanolone.
3.Characterization of binding sites for the omega3 receptor ligands [3H]PK11195 and [3H]RO5-4864 in human brain.
Rao VL;Butterworth RF Eur J Pharmacol. 1997 Dec 4;340(1):89-99.
The kinetics and pharmacology of the isoquinoline and benzodiazepine binding sites of the omega3 or peripheral-type benzodiazepine receptors were studied using the specific ligands [3H] 7-chloro-5-(4-chlorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin -2-one ([3H]PK11195) and [3H]1-(2-Chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarb oxamide ([3H]RO5-4864), respectively. Binding of both ligands was saturable, reversible, displayed nanomolar affinity, and best fit to a single site model. Occipital cortex and cerebellum displayed highest and lowest densities of binding sites respectively; for both ligands. Bmax values of [3H]PK11195 were several-fold higher than that of [3H]RO5-4864 in all regions studied consistent with their binding to distinct subunits of the human peripheral-type benzodiazepine receptor heteromeric complex. However, the isoquinoline and benzodiazepine ligands were found to be mutually competitive at nanomolar concentrations suggesting allosteric interactions between these two sites. Competition binding experiments showed that the binding of both ligands was displaced by diazepam with Ki values in the nM range, and by clonazepam in the microM range. The novel peripheral-type benzodiazepine receptor ligand 2-(4-fluorophenyl)-N,N-di-n-hexyl-1H-indole-3-acetamide (FGIN1-27) displaced only [3H]PK11195 binding with high potency.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related GABA Receptor Products


CAS 62666-20-0 Progabide

Progabide
(CAS: 62666-20-0)

Progabide is a gamma-aminobutyric acid (GABA) antagonist. It has agonistic activity for both the GABAA and GABAB receptors. It has antiepileptic activity and is...

CAS 123557-91-5 rac BHFF

rac BHFF
(CAS: 123557-91-5)

BHFF is a positive allosteric modulator of GABAB receptor that increases the potency and efficacy of GABA. BHFF displays anxiolytic activity in vivo.

CAS 1758-80-1 L-DABA

L-DABA
(CAS: 1758-80-1)

L-DABA, (L-2,4-Diaminobutyric acid) is a noncompetitive GABA transaminase inhibitor (IC50> 500 μM) with antitumor activity in vivo and in vitro.

CAS 130477-52-0 L-655,708

L-655,708
(CAS: 130477-52-0)

L-655,708, an inverse agonist of α5 subunit involved in GABAA receptor, has been found to exhibit cognitive performance improvement in biological studies.

CAS 57717-80-3 CGP7930

CGP7930
(CAS: 57717-80-3)

CGP7930 is a positive allosteric modulator at the GABAB receptor. It has anxiolytic effects in animal studies, and has a synergistic effect with GABAB agonists ...

CAS 1259477-42-3 CP 615003 mesylate

CP 615003 mesylate
(CAS: 1259477-42-3)

CP 615003 mesylate is a potent and selective GABAA receptor partial agonist potentially useful in treating generalized anxiety disorder.

CAS 38090-53-8 TACA

TACA
(CAS: 38090-53-8)

TACA, the trans-isomer of CACA, is a potent GABAA and GABAC agonist, GABA uptake inhibitor and substrate for GABA-T. It also acts as a GABAA-ρ agonist.

CAS 54-95-5 Cardiazole

Cardiazole
(CAS: 54-95-5)

Cardiazole is a GABA(A) receptor antagonist, causes alterations in excitatory and inhibitory neurotransmitter systems.

Chemical Structure

CAS 142720-24-9 FGIN-1-27

Quick Inquiry

Verification code

Featured Items